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 Increased rates in black women, compared to white, and average younger age at diagnosis  Hispanic women had increased rates and younger age at diagnosis compared to non-Hispanic women  Highest incidence in the South Watson M, Saraiya M, Giuliano A, et al. Burden of cervical cancer in the United States, 1998 -2003 . Cancer 2008 113:2855 -2864  Age-adjusted incidence rates were 3 times higher for men than women for all sites  Incidence rates also higher among blacks, higher among non-Hispanics than Hispanics, and higher among those who lived in the South  More likely to be diagnosed at a late stage than non-HPV associated oral cancer  Annual incidence rate has increased over the past 3 decades  80%-93% of anal cancers are associated with HPV, mainly 16 and 18  Average annual count of 3566 cases of invasive anal cancer  85% SCC  14% AC, 1% small cell/NE  Effect of vaccines will depend on efficacy against anal and oropharyngeal infections  Vaccination must precede infection -peripartum or oral transmission?  No screening for HPV-associated non-cervical cancers, thus vaccination may have greatest potential in prevention  It is unlikely that nonmandatory vaccination of adolescent females will lead to significant herd immunity  Future vaccines with more high-risk types will add limited benefit, except for cervical cancer
